

Venture Capital IPO Report

1st Half, 2011 – United States

Technology Venture Capital-Backed U.S. Company IPOs

Publisher: VentureDeal



Contents						
IPO Activity						
Digital Media • Internet • IT	2					
Biotechnology • Pharmaceutical	3					
Other Technology	4					
Table 1: Venture Capital IPO Activity	5					
Notes	6					



IPO Activity

Summary During the first half of calendar year 2011, 23 venture capital-backed U.S. technology companies went public, raising a total of \$3.79 billion in gross offering proceeds. This compares positively to the \$2.5 billion raised during the second half of 2010, resulting in a 51% increase in total amount raised.

10 Digital Media, Internet and IT venture-backed companies had IPOs resulting in \$1.67 billion total consideration. 5 life science companies raised \$282 million in gross proceeds. 8 companies in the remaining sectors of Semiconductors, Networking, Transportation, Alternative Energy, Wireless and Components garnered \$1.8 billion from public investors.

With respect to pricing, 10 IPOs priced above their expected range. 6 priced within the expected original or revised range and the remaining 7 companies priced below the original range sought. This represents a material improvement in pricing power versus the second half of 2010. As of 7/31/2011, 15 of 23 IPO share prices were higher than their initial flotation price, compared to 20 of 23 IPOs in the previous period.

Digital Media • Internet • IT

Digital Media One Digital Media company went public during the first half of 2011: <u>Responsys</u> (NASDAQ: MKTG).

Responsys raised \$74.2 million in its IPO, which priced at \$12 per share, above the original per share range. The company was funded by <u>Accel</u>, <u>Foundation Capital</u>, <u>Sigma Partners</u>, and <u>Redpoint Ventures</u>. Responsys is a digital media company with worldwide reach. It develops software for companies to enable relationship marketing with customers and network users.

Internet Five Internet companies went public during the first half of the year.

<u>Demand Media</u> (NYSE: DMD). The IPO for Demand Media raised funds totaling \$151.3 million with an original range of \$14-\$16 per share.

This material has been prepared and issued by VentureDeal, LLC. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity. © 2011 VentureDeal. <u>Some Rights Reserved</u>.



Demand Media (NYSE:DMD) has traded at a 52-week high of 27.38 and low of \$10.14. The company creates timely context and video which sync with pertinent advertising. Demand Media collects user profiles, comments and discussion forums. Within its domain registry, it has 10 million unique domain names under control.

Business-oriented social networking company <u>LinkedIn</u> (NYSE: LNKD) went public with the second-largest IPO of the first half, raising \$352.8 million at a share price of \$45, which was within an upwardly revised range. The original range was \$32-\$35. LinkedIn was backed by prominent venture capital firms <u>Sequoia Capital</u>, <u>Bessemer Venture</u> <u>Partners</u> and <u>Greylock Partners</u>.

IT There were four IPOs during the second half of the year for the IT (Information Technologies) industry, with gross proceeds totaling \$502 million.

San Mateo, California-based Epocrates (NASDAQ: EPOC), which was founded in 1998 and raised \$86.4 million at a price of \$16 per share, above the original range of \$13-\$15. Epocrates says that more than 1.3 million healthcare professionals - 45% of US-based physicians use its systems to improve their practice efficiency with its "drug reference, educational and clinical apps." The company was backed by a large syndicate of venture capital and private equity firms.

Biotechnology • Pharmaceutical

Biotechnology There were two biotechnology IPOs during the first half of the year, raising \$75 million each.

The <u>Fluidigm</u> (NASDAQ: FLDM) IPO raised \$75 million in gross proceeds for this high-tech nanotechnology company. The offering opened for trading within its expected range. The bioengineering products that Fluidigm has invented enable measurement of chemicals at the nanoliter scale. Venture capital firms that invested in the company include: <u>Alloy Ventures</u>, <u>EuclidSR</u>, <u>InterWest</u> and <u>Versant</u> <u>Ventures</u>.

This material has been prepared and issued by VentureDeal, LLC. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity. © 2011 VentureDeal. <u>Some Rights Reserved</u>.



Pharmaceutical Three venture capital-backed Pharmaceutical companies went public, raising \$132 million in aggregate gross proceeds, and represented the second most active VC backed industry for IPOs during 1H 2011.

<u>AcelRx Pharmaceuticals</u> (NASDAQ: ACRX) secured \$40 million in its IPO, which floated below the anticipated price range. AcelRx develops breakthrough medicines for acute pain management that can be administered within a physician's office. Venture capital firms that invested in the company included: <u>Three Arch Partners</u>, <u>Skyline</u> <u>Ventures</u>, <u>Alta Partners</u> and <u>Kaiser Permanente</u>.

- OtherThere were 8 IPOs covering the remaining technology sectors of
Semiconductors, Networking, Transportation, Alternative Energy,
Wireless and Components. Aggregate gross proceeds totaled \$1.8
billion.
- Alternative Solazyme (NASDAQ: SZYM) transforms organic materials such as algae into oils and other bioproducts. Resulting products include fuel, skin-care, dietary supplements, and personal care. The IPO priced at \$18 per share, which was above the anticipated range of \$15-\$17. Roda Group, Lightspeed Venture Partners, and Braemar Energy were investors. Funds raised from the IPO totaled \$197.55 million.
- Semiconductors Freescale Semiconductor (NYSE: FSL) floated the largest IPO of the six month period, raising \$783 million. The IPO went out significantly below its estimated range, pricing at \$18 per share versus a range of \$22-\$24 per share. Blackstone, The Carlyle Group, Permira, and TPG were company investors. The company produces microcontrollers which are used in OEMs and by distributors that deploy embedded microprocessors.

Table 1 is on the following page

This material has been prepared and issued by VentureDeal, LLC. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity. © 2011 VentureDeal. <u>Some Rights Reserved</u>.



Table 1

Venture Capital IPO Activity – 1st Half 2011 (Sorted by IPO date)

Company Name	Ticker	Industry	IPO Date	IPO Amount	IPO Price	7.31.11 Price	% Change
Demand Media	<u>DMD</u>	Internet	1/26/2011	\$151,300,000	\$17.00	\$10.14	-40%
NeoPhotonics	<u>NPTN</u>	Networking	2/2/111	\$82,500,000	\$11.00	\$7.38	-33%
Epocrates	EPOC	IT	2/2/2011	\$86,400,000	\$16.00	\$16.44	3%
Pacira Pharmaceuticals	<u>PCRX</u>	Pharmaceuticals	2/3/2011	\$42,000,000	\$7.00	\$10.02	43%
Endocyte	<u>ECYT</u>	Biotechnology	2/4/2011	\$75,000,000	\$6.00	\$13.33	122%
Gevo	<u>GEVO</u>	Alt. Energy	2/9/2011	\$107,250,000	\$15.00	\$16.53	10%
Fluidigm	<u>FLDM</u>	Biotechnology	2/10/2011	\$75,000,000	\$13.50	\$16.96	26%
AcelRx Pharmaceuticals	<u>ACRX</u>	Pharmaceuticals	2/11/2011	\$40,000,000	\$8.00	\$4.14	-48%
Cornerstone OnDemand	<u>CSOD</u>	IT	3/17/2011	\$136,500,000	\$13.00	\$16.40	26%
ServiceSource	<u>SREV</u>	IT	3/25/2011	\$119,400,000	\$10.00	\$18.66	87%
Tranzyme Pharma	<u>TZYM</u>	Pharmaceuticals	4/1/2011	\$54,000,000	\$4.00	\$3.97	-1%
Zipcar	<u>ZIP</u>	Transportation	4/13/2011	\$174,240,000	\$18.00	\$23.28	29%
Responsys	<u>MKTG</u>	Digital Media	4/20/2011	\$74,200,000	\$12.00	\$14.57	21%
RPX	<u>RPXC</u>	IT	5/4/2011	\$160,178,000	\$19.00	\$26.75	41%
Boingo Wireless	<u>WIFI</u>	Wireless	5/4/2011	\$77,895,000	\$13.50	\$8.77	-35%
LinkedIn	<u>LNKD</u>	Internet	5/18/2011	\$352,800,000	\$45.00	\$101.03	125%
Active Network	<u>ACTV</u>	Internet	5/24/2011	\$165,000,000	\$15.00	\$18.15	21%
Freescale Semiconductor	<u>FSL</u>	Semiconductors	5/25/2011	\$783,000,000	\$18.00	\$16.33	-9%
Solazyme	<u>SZYM</u>	Alt. Energy	5/27/2011	\$197,550,000	\$18.00	\$22.85	27%
Fusion-io	<u>FIO</u>	Components	6/8/2011	\$233,700,000	\$19.00	\$29.61	56%
Pandora	<u>P</u>	Internet	6/14/2011	\$235,200,000	\$16.00	\$15.09	-6%
Kior	<u>KIOR</u>	Alt. Energy	6/23/2011	\$150,000,000	\$15.00	\$14.45	-4%
HomeAway	<u>AWAY</u>	Internet	6/28/2011	\$216,000,000	\$27.00	\$39.31	46%

Total Tech VC IPOs

23

\$3,789,113,000

This material has been prepared and issued by VentureDeal, LLC. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity. © 2011 VentureDeal. <u>Some Rights Reserved</u>.



Notes

This report was prepared by the staff of VentureDeal, LLC.

The information source used was the <u>VentureDeal.com</u> database and reputable online resources. VentureDeal is a venture capital database that provides the latest information about venture-backed technology companies, venture capital firms and transactions in the United States.

The database obtains transaction and company information from a wide variety of reputable public and private sources. While this report is free of charge, users may view the individual transactions supporting the totals herein by subscribing to VentureDeal.

This publication may be re-produced or re-transmitted for noncommercial purposes, subject to the copyright notice herein.

While all attempts have been made to verify information provided in this publication, neither the author nor the publisher assumes any responsibility for errors, omissions or contrary interpretation of the subject matter herein.

This publication is not intended for use as a source of any advice such as legal, medical, financial or accounting. The information contained herein may be subject to varying international, federal, state and/or local laws or regulations. The purchaser or reader of this publication assumes responsibility for the use of these materials and information. Adherence to all applicable laws and regulations, including international, federal, state and local, governing professional licensing, business practices, advertising and all other aspects of doing business in the US, Canada or any other jurisdiction is the sole responsibility of the purchaser or reader. Neither the author nor the Publisher assume any responsibility or liability whatsoever on the behalf of any purchaser or reader of these materials.

This material has been prepared and issued by VentureDeal, LLC. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity. © 2011 VentureDeal. <u>Some Rights Reserved</u>.